Data from the A1chieve® study, evaluating adverse events and effectiveness of Novo Nordisk insulins (NovoMix 30, Levemir and NovoRapid) in 66,726 people with type 2 diabetes, shows that type 2 diabetes patients can significantly improve their blood glucose control with a low occurrence of low blood sugar (hypoglycemia). The study showed that before treatment with a Novo Nordisk insulin analog was initiated, the average blood glucose control (HbA1c) among the 66,726 study participants was 9.5%, which is well above the internationally recognized target of 7%. The study was published in the journal Diabetes Research and Clinical Practice
Poor blood glucose control puts people at high risk of developing diabetes-related complications; in this study up to 80% of people had diabetes complications and 75% already had cardiovascular diseases. After 24 weeks of treatment with a Novo Nordisk insulin analog there was a significant reduction in HbA1c levels of 2.1%, from 9.5% to 7.4%.1 Reported rates of overall hypoglycemia slightly increased in those new to insulin and fell in those who switched from other insulin therapies. Furthermore, patients reported quality of life improved significantly.
A1chieve® is the largest study ever into the safety and effectiveness of insulin treatment and involves 66,726 people with type 2 diabetes from 28 countries across Asia, Africa, Europe and Latin America. Before entering into the study, people were started on one of three Novo Nordisk insulin analog regimens based on their physician’s clinical judgement. The primary aim of the study was to evaluate the clinical safety of the study insulins in routine clinical practice, assessed by the incidence of serious adverse drug reactions (SADRs) including rates of major hypoglycemia.
After 24 weeks, clinically meaningful improvements in overall blood glucose control were found with all three insulin analog regimens:
For people taking premix insulin NovoMix® 30, HbA1c decreased from 9.5% to 7.3% for insulin-naive (18,459 people) and from 9.4% to 7.5% for prior insulin users (8574 people).
In people taking the long-acting insulin Levemir®, HbA1c decreased from 9.5% to 7.4% for insulin-naive (8,459 people) and from 9.3% to 7.6 % for prior insulin users (2,122 people).
For people taking the fast-acting meal-time insulin NovoRapid® in combination with a basal insulin, HbA1c decreased from 10.1% to 7.3% for insulin-naive (1,127 people) and from 9.4% to 7.5% for prior insulin users (1,869 people).
Reported rates of overall hypoglycemia slightly increased in those new to insulin, from 1.07 to 1.19 events/person/year, and fell in those who switched from other insulin therapies from 7.31 to 2.48 events/person/year. The total rate of reported SADRs after initiation of insulin analog was 0.13 events/100 patient-years.